<DOC>
	<DOCNO>NCT00149708</DOCNO>
	<brief_summary>Growth hormone ( GH ) deficiency ( GHD ) adulthood associate change body composition ( e.g . increase abdominal obesity , reduce muscle mass ) , organ function ( e.g . reduce cardiac systolic function ) , metabolic parameter link increase risk cardiovascular disease ( e.g . increase serum total LDL cholesterol , C reactive protein , plasma fibrinogen ) , reduce bone density . These observation use define `` adult GHD syndrome '' advocate GH replacement therapy GHD adult . However , study perform patient hypothalamic pituitary disease , and/or undergone brain irradiation . Such patient often chronically sick , commonly lack pituitary hormone , whose replacement therapy may fully restore physiological function under-active gland . Reliable data existence AGHD syndrome response GH therapy obtain study patient otherwise healthy . However , isolate GH deficiency ( IGHD ) rare disease . In addition , 50 % patient diagnose IGHD childhood longer GH deficient adult , make study difficult perform due scarcity patient population . We identify large homogeneous population patient IGHD due homozygous mutation GHRH-receptor ( GHRHR ) gene reside rural area Brazil . None adult dwarf patient ever treat hGH replacement . This population represent unique model study effect isolate lifetime lack GH . We propose study physiological metabolic parameter subject homozygous mutation compare normal subject reside community . The primary goal proposal determine consequence life-long lack GH body composition , muscle strength , cardiovascular status , cardiovascular risk factor , thyroid status bone density metabolism , test parameter reverse 6-month course GH replacement therapy . In addition , want test hypothesis heterozygosity GHRHR mutation cause phenotype may intermediate one present homozygous normal subject homozygous affect GHD patient . This relevant inactivating mutation GHRHR describe increase frequency population different genetic background , suggest individual faulty single GHRHR allele may present significant number general population .</brief_summary>
	<brief_title>Consequence Lifetime Isolated Growth Hormone Deficiency</brief_title>
	<detailed_description>SPECIFIC AIM 1 : To study anthropometric parameter , cardiovascular metabolic status cardiovascular risk profile , include inflammatory marker cardiovascular relevance , muscle strength , bone density bone metabolism , thyroid status twenty GH-na√Øve adult GHD subject homozygous null GHRHR mutation compare twenty age- sex- match normal control population . SPECIFIC AIM 2 : To observe change parameter occur GHD subject 6-months treatment hGH replacement , reversibility 6-months washout period . SPECIFIC AIM 3 : To determine effect heterozygosity GHRHR mutation . To end , propose genotype large number apparently normal member Itabaianinha community goal separate subject homozygous wild-type allele subject heterozygous GHRHR mutation , compare phenotype one observed subject homozygous wild type allele reside geographical area . Together , study determine effect lifetime absence GH multiple organ function response hGH therapy , tell heterozygosity mutation GHRHR gene associate detectable phenotype .</detailed_description>
	<mesh_term>Endocrine System Diseases</mesh_term>
	<mesh_term>Dwarfism , Pituitary</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Lifetime isolate untreated growth hormone deficiency Age 18 year , pregnancy , diabetes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Growth hormone</keyword>
	<keyword>Deficiency</keyword>
	<keyword>Cardiovascular risk</keyword>
	<keyword>Body composition</keyword>
</DOC>